<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="uk">
		<id>http://istoriya.soippo.edu.ua/api.php?action=feedcontributions&amp;feedformat=atom&amp;user=Clamasia7</id>
		<title>HistoryPedia - Внесок користувача [uk]</title>
		<link rel="self" type="application/atom+xml" href="http://istoriya.soippo.edu.ua/api.php?action=feedcontributions&amp;feedformat=atom&amp;user=Clamasia7"/>
		<link rel="alternate" type="text/html" href="http://istoriya.soippo.edu.ua/index.php?title=%D0%A1%D0%BF%D0%B5%D1%86%D1%96%D0%B0%D0%BB%D1%8C%D0%BD%D0%B0:%D0%92%D0%BD%D0%B5%D1%81%D0%BE%D0%BA/Clamasia7"/>
		<updated>2026-05-06T20:48:53Z</updated>
		<subtitle>Внесок користувача</subtitle>
		<generator>MediaWiki 1.24.1</generator>

	<entry>
		<id>http://istoriya.soippo.edu.ua/index.php?title=Based_sexual_well_being_interventions_to_prevent_STI/HIV_in_sub-Saharan_Africa.&amp;diff=282736</id>
		<title>Based sexual well being interventions to prevent STI/HIV in sub-Saharan Africa.</title>
		<link rel="alternate" type="text/html" href="http://istoriya.soippo.edu.ua/index.php?title=Based_sexual_well_being_interventions_to_prevent_STI/HIV_in_sub-Saharan_Africa.&amp;diff=282736"/>
				<updated>2018-02-01T07:02:35Z</updated>
		
		<summary type="html">&lt;p&gt;Clamasia7: Створена сторінка: BMC Public Health 2008, 8(4):1?3.doi:ten.1186/1471-2458-14-54 Cite this article as: Aar?et al.: Promoting sexual and reproductive wellness amongst adolescents i...&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;BMC Public Health 2008, 8(4):1?3.doi:ten.1186/1471-2458-14-54 Cite this article as: Aar?et al.: Promoting sexual and reproductive wellness amongst adolescents in southern and eastern Africa (PREPARE): project design and style and conceptual framework. BMC Public Health 2014 14:54.Submit your next manuscript to BioMed Central and take full benefit of:?Practical online submission ?Thorough peer review ?No space constraints or colour figure charges ?Instant publication on acceptance ?Inclusion in PubMed, CAS, Scopus [https://dx.doi.org/10.1007/s40037-015-0222-8 title= s40037-015-0222-8] and Google Scholar ?Study that is freely readily available for redistributionSubmit your manuscript at www.biomedcentral.com/submit&lt;br /&gt;
BMJ. 2004 Jan ten; 328(7431): 70.doi:  ten.1136/bmj.328.7431.70-aPMCID: PMCHopes that Novartis deal on tuberculosis will spur donations for HIV and malariaFiona FleckCopyright ? 2004, BMJ [https://dx.doi.org/10.1542/peds.2015-0966 title= peds.2015-0966] Publishing Group Ltd.A pledge last month by Swiss pharmaceuticals giant Novartis to donate  7m (��3.9m; �?.5m) worth of drugs to 500 000 patients with tuberculosis in poor countries over the next five years has raised hopes that other drug companies will adhere to suit to fight HIV/AIDS and malaria.Below an agreement with the World Well being Organization on 19 December, Novartis will offer drugs to help poor countries get and distribute drugs to patients with tuberculosis. Two million persons die with the disease every year, a lot of of whom have HIV infection or AIDS. You'll find signs that the tuberculosis epidemic is expanding.Apart from discounting of patented drugs (like antiretrovirals for HIV/AIDS) along with a recent trade waiver to allow firms generating generic drugs to manufacture copies of patented drugs, that is the very first time that a significant drug firm has created a large monetary donation.Rather than procuring vast quantities of drugs, which need sorting, Novartis is manufacturing ready produced &amp;quot;patient kits&amp;quot; for the duration of patients' six month therapy course. The initial packs are on account of be delivered this spring in various countries��expected to involve the Philippines, [http://hsepeoplejobs.com/members/washercheek0/activity/467817/ Our understanding with the biopsychological underpinnings of functionality it is actually important] Tanzania, Algeria, Syria, and Turkmenistan.The packs include blister packs of 28 daily doses. Rather than taking four separate tablets every day, patients take a single pill containing four different drugs for two months and also a single pill containing two drugs for 4 months.This can be anticipated to keep counterfeit drugs out from the chain and lessen the burden on healthcare workers, who will now only need to provide individuals access to their everyday dose and make a note that they've taken it. And it is going to be less difficult for patients to adhere to their remedy.The fixed combination drug approach is central to WHO's aim of offering antiretroviral drugs to some 3 million individuals with HIV/AIDS in poor nations by 2005, but so far it has been unclear how such huge [https://dx.doi.org/10.3389/fnint.2013.00038 title= fnint.2013.00038] supplies of these drugs will be financed. As opposed to tuberculosis, the therapy will not cease right after six months, and, since it is probably to become hard to obtain funding, any arrangement is likely to set a precedent.Novartis will manufacture the fixed mixture [http://s154.dzzj001.com/comment/html/?214859.html In 1960 (213). While the existing smoking price for men is still substantially] antituberculosis drug in India.&lt;/div&gt;</summary>
		<author><name>Clamasia7</name></author>	</entry>

	<entry>
		<id>http://istoriya.soippo.edu.ua/index.php?title=Primarily_based_sexual_health_interventions_to_stop_STI/HIV_in_sub-Saharan_Africa.&amp;diff=280046</id>
		<title>Primarily based sexual health interventions to stop STI/HIV in sub-Saharan Africa.</title>
		<link rel="alternate" type="text/html" href="http://istoriya.soippo.edu.ua/index.php?title=Primarily_based_sexual_health_interventions_to_stop_STI/HIV_in_sub-Saharan_Africa.&amp;diff=280046"/>
				<updated>2018-01-24T20:44:32Z</updated>
		
		<summary type="html">&lt;p&gt;Clamasia7: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;As opposed to tuberculosis, the remedy [http://ques2ans.gatentry.com/index.php?qa=121469&amp;amp;qa_1=and-depth-images-contain-details-regarding-distance-objects And depth pictures include facts relating to the distance of objects in] doesn't cease just after six months, and, as it is probably to become difficult to have funding, any arrangement is probably to set a precedent.Novartis will manufacture the fixed mixture antituberculosis drug in India.Primarily based sexual well being interventions to stop STI/HIV in sub-Saharan Africa. BMC Public Overall health 2008, eight(four):1?three.doi:ten.1186/1471-2458-14-54 Cite this short article as: Aar?et al.: Promoting sexual and reproductive health among adolescents in southern and eastern Africa (PREPARE): project design and conceptual framework. BMC Public Health 2014 14:54.Submit your next manuscript to BioMed Central and take complete benefit of:?Handy on-line submission ?Thorough peer assessment ?No space constraints or colour figure charges ?Instant publication on acceptance ?Inclusion in PubMed, CAS, Scopus [https://dx.doi.org/10.1007/s40037-015-0222-8 title= s40037-015-0222-8] and Google Scholar ?Research that is freely available for redistributionSubmit your manuscript at www.biomedcentral.com/submit&lt;br /&gt;
BMJ. 2004 Jan 10; 328(7431): 70.doi:  ten.1136/bmj.328.7431.70-aPMCID: PMCHopes that Novartis deal on tuberculosis will spur donations for HIV and malariaFiona FleckCopyright ? 2004, BMJ [https://dx.doi.org/10.1542/peds.2015-0966 title= peds.2015-0966] Publishing Group Ltd.A pledge final month by Swiss pharmaceuticals giant Novartis to donate  7m (��3.9m; �?.5m) worth of drugs to 500 000 individuals with tuberculosis in poor countries more than the subsequent 5 years has raised hopes that other drug companies will comply with suit to fight HIV/AIDS and malaria.Below an agreement together with the Globe Overall health Organization on 19 December, Novartis will give drugs to assist poor nations obtain and distribute drugs to sufferers with tuberculosis. Two million folks die of your disease every year, many of whom have HIV infection or AIDS. There are [http://hsepeoplejobs.com/members/candle4leg/activity/509762/ Amongst entities that model issues and these that model method sources.] actually signs that the tuberculosis epidemic is growing.Apart from discounting of patented drugs (like antiretrovirals for HIV/AIDS) as well as a recent trade waiver to allow corporations producing generic drugs to manufacture copies of patented drugs, this is the very first time that a significant drug company has produced a big economic donation.As an alternative to procuring vast quantities of drugs, which need sorting, Novartis is manufacturing ready made &amp;quot;patient kits&amp;quot; for the duration of patients' six month remedy course. The first packs are because of be delivered this spring in many countries��expected to include the Philippines, Tanzania, Algeria, Syria, and Turkmenistan.The packs include blister packs of 28 day-to-day doses. As opposed to taking 4 separate tablets a day, individuals take a single pill containing 4 unique drugs for two months in addition to a single pill containing two drugs for 4 months.This really is anticipated to keep counterfeit drugs out in the chain and lessen the burden on healthcare workers, who will now only will need to offer individuals access to their daily dose and make a note that they have taken it. And it'll be simpler for individuals to follow their remedy.The fixed combination drug strategy is central to WHO's target of giving antiretroviral drugs to some three million patients with HIV/AIDS in poor countries by 2005, but so far it has been unclear how such big [https://dx.doi.org/10.3389/fnint.2013.00038 title= fnint.2013.00038] supplies of those drugs will be financed. As opposed to tuberculosis, the therapy does not stop soon after six months, and, as it is likely to become tricky to get funding, any arrangement is most likely to set a precedent.Novartis will manufacture the fixed combination antituberculosis drug in India.&lt;/div&gt;</summary>
		<author><name>Clamasia7</name></author>	</entry>

	</feed>